13 August 2024 | 8:42AM EDT Boundless Bio Inc. (BOLD): 2024 Update: Proof of Concept data for both '355 and '825 now expected in 2H25. With measures, cash Boundless Bio reported 2024 financial results including program updates. With lead asset BBI-355 (CHK1 inhibitor), management stated that in the Phase 1/2 POTENTIATE trial thus far, no safety signals have been observed including importantly, no evidence of toxicities in the combination dose escalation cohorts. The pace of enrollment in the study, however, ...